Entry Instance

HTTP 200 OK
Allow: GET, PUT, PATCH, DELETE, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "id": 1378488,
    "url": "https://info.mzalendo.com/api/v0.1/hansard/entries/1378488/?format=api",
    "text_counter": 144,
    "type": "speech",
    "speaker_name": "Endebess, UDA",
    "speaker_title": "Hon (Dr) Robert Pukose",
    "speaker": null,
    "content": "The IVI Agreement was submitted to Hon. Speaker of the National Assembly on 21st August 2023, upon its approval by the Cabinet on 6th December 2022. It was subsequently tabled before the House on Wednesday, 23rd August 2023, for consideration and approval of its ratification. It was committed to the Departmental Committee on Health for consideration and reporting to the House, pursuant to Section 8 of the Treaty Making and Ratification Act and Standing Order 216 (5)(f)(fa). The IVI is founded on the belief that the health of children in the developing countries can dramatically be improved by development, introduction and use of new improved vaccines. It realises this by: 1. Providing training and technical assistance in the production, technology and research of vaccines. 2. Conducting laboratory and field-based research and development. 3. Supporting and conducting clinical trials and field evaluation of new vaccines to facilitate and promote introduction of new and improved vaccines. 4. Co-operating with vaccine manufacturers and national control authorities and other relevant bodies in developed and developing countries to promote vaccine research and development. Kenya will, therefore, greatly benefit from its membership in IVI in many ways. I will highlight a few. The membership will enable knowledge transfer, capacity building in biotechnology and vaccine production. This is crucial as vaccine research, development and field research are catalysts to the attainment to Universal Health Coverage (UHC). The Technical and hands-on training to develop skill sets across vaccine development and production process, disease surveillance, biopharmaceutical manufacturing, biosafety and good manufacturing practices requirements are also essential and beneficial to the realisation of UHC and economic growth. The IVI will open up Kenya to network of vaccine producers, as well as consortia and networks of researchers in health matters."
}